Table 2 VE of mRNA-1273 against infection and hospitalization with Delta or Omicron variants

From: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

  

SARS-CoV-2 test positive

SARS-CoV-2 test negative

VE (95% CI)a

 

Variant

Vaccinated (%)

Unvaccinated (%)

Vaccinated (%)

Unvaccinated (%)

Unadjusted

Adjusted

Infectionb,c

       

 One-dose

Delta

59 (2.0%)

2,883 (98.0%)

218 (3.7%)

5,666 (96.3%)

47.0% (29.0%, 60.4%)

56.7% (40.7%, 68.4%)

Omicron

357 (4.0%)

8,590 (96.0%)

843 (4.7%)

17,051 (95.3%)

15.8% (4.5%, 25.8%)

20.4% (9.5%, 30.0%)

 Two-dose

Delta

1,234 (30.0%)

2,883 (70.0%)

4,031 (49.0%)

4,203 (51.0%)

57.0% (53.3%, 60.4%)

63.6% (59.9%, 66.9%)

14–90 days

21 (0.7%)

2,883 (99.3%)

151 (3.5%)

4,203 (96.5%)

79.7% (67.9%, 87.2%)

80.2% (68.2%, 87.7%)

91–180 days

87 (2.9%)

2,883 (97.1%)

342 (7.5%)

4,203 (92.5%)

62.9% (52.9%, 70.8%)

68.9% (60.1%, 75.8%)

181–270 days

824 (22.2%)

2,883 (77.8%)

2,663 (38.8%)

4,203 (61.2%)

54.9% (50.6%, 58.8%)

63.7% (59.8%, 67.2%)

>270 days

302 (9.5%)

2,883 (90.5%)

875 (17.2%)

4,203 (82.8%)

49.7% (42.2%, 56.2%)

61.3% (55.0%, 66.7%)

Omicron

10,795 (55.7%)

8,600 (44.3%)

22,679 (58.5%)

16,111 (41.5%)

11.2% (8.0%, 14.3%)

13.9% (10.5%, 17.1%)

14–90 days

245 (2.8%)

8,600 (97.2%)

836 (4.9%)

16,111 (95.1%)

45.1% (36.5%, 52.5%)

44.0% (35.1%, 51.6%)

91–180 days

783 (8.3%)

8,600 (91.7%)

1,867 (10.4%)

16,111 (89.6%)

21.4% (14.3%, 28.0%)

23.5% (16.4%, 30.0%)

181–270 days

7,015 (44.9%)

8,600 (55.1%)

14,759 (47.8%)

16,111 (52.2%)

11.0% (7.5%, 14.3%)

13.8% (10.2%, 17.3%)

>270 days

2,752 (24.2%)

8,600 (75.8%)

5217 (24.5%)

16,111 (75.5%)

1.2% (−4.0%, 6.3%)

5.9% (0.4%, 11.0%)

 Three-dose

Delta

138 (4.6%)

2,883 (95.4%)

1,836 (30.4%)

4,206 (69.6%)

93.6% (92.0%, 95.0%)

94.5% (92.9%, 95.7%)

14–60 days

112 (3.7%)

2,883 (96.3%)

1,658 (28.3%)

4,206 (71.7%)

90.1% (88.0%, 91.9%)

93.7% (92.2%, 94.9%)

>60 days

26 (0.9%)

2,883 (99.1%)

178 (4.1%)

4,206 (95.9%)

78.7% (67.8%, 85.9%)

86.0% (78.1%, 91.1%)

Omicron

2,617 (23.3%)

8,600 (76.7%)

10,203 (45.5%)

12,231 (54.5%)

71.5% (69.7%, 73.1%)

70.0% (68.0%, 71.9%)

14–60 days

2,127 (19.8%)

8,600 (80.2%)

9,121 (42.7%)

12,231 (57.3%)

66.8% (65.0%, 68.6%)

71.6% (69.7%, 73.4%)

>60 days

490 (5.4%)

8,600 (94.6%)

1,082 (8.1%)

12,231 (91.9%)

35.6% (28.1%, 42.3%)

47.4% (40.5%, 53.5%)

 Three-dose excluding immunocompromised patients

Delta

124 (4.2%)

2,851 (95.8%)

1,708 (29.5%)

4,089 (70.5%)

89.6% (87.4%, 91.4%)

93.7% (92.2%, 94.9%)

14–60 days

104 (3.5%)

2,851 (96.5%)

1,580 (27.9%)

4,089 (72.1%)

90.6% (88.4%, 92.3%)

94.2% (92.7%, 95.3%)

>60 days

20 (0.7%)

2,851 (99.3%)

128 (3.0%)

4,089 (97.0%)

77.6% (64.0%, 86.0%)

88.1% (80.2%, 92.9%)

Omicron

2,464 (22.5%)

8,479 (77.5%)

9,677 (44.8%)

11,925 (55.2%)

64.2% (62.3%, 66.0%)

70.5% (68.6%, 72.4%)

14–60 days

2,059 (19.5%)

8,479 (80.5%)

8,803 (42.5%)

11,925 (57.5%)

67.1% (65.2%, 68.9%)

72.1% (70.2%, 73.9%)

>60 days

405 (4.6%)

8,479 (95.4%)

874 (6.8%)

11,925 (93.2%)

34.8% (26.4%, 42.3%)

51.2% (44.2%, 57.3%)

Hospitalizationb,d

       

 One-dose

Deltae

1 (1.3%)

79 (98.8%)

10 (6.3%)

150 (93.8%)

82.2% (−31.4%, 97.8%)

71.2% (−68.7%, 97.4%)

Omicron

0 (0.0%)

14 (100.0%)

2 (7.1%)

26 (92.9%)

100.0% (N/A)

N/A

 Two-dose

Deltae

4 (4.8%)

79 (95.2%)

94 (56.6%)

72 (43.4%)

95.9% (86.9%, 98.7%)

99.0% (93.3%, 99.9%)

Omicronf

7 (33.3%)

14 (66.7%)

28 (66.7%)

14 (33.3%)

81.1% (29.8%, 94.9%)

84.5% (23.0%, 96.9%)

 Three-dose

Deltae

1 (1.3%)

79 (98.8%)

69 (43.1%)

91 (56.9%)

98.3% (87.7%, 99.8%)

99.7% (96.5%, 100.0%)

Omicrong

4 (22.2%)

14 (77.8%)

26 (72.2%)

10 (27.8%)

89.0% (58.5%, 97.1%)

99.2% (76.3%, 100.0%)

  1. aWhen the OR or its 95% CI was >1, the VE or its 95% CI was transformed as −(1 − [1/adjusted OR]) × 100 (ref. 24).
  2. bModels for time since vaccination analyses and three-dose hospitalization analyses are unconditional logistic models with adjustment for matching variables.
  3. cModel adjusted for core variables: history of SARS-CoV-2 molecular test; preventive care; number of outpatient and virtual visits; Charlson comorbidity score; obesity (yes/no/unknown); frailty index; specimen type; immunocompromised status and history of COVID-19.
  4. dModel adjusted for core variables: history of SARS-CoV-2 molecular test; preventive care; Charlson comorbidity score; obesity (yes/no/unknown); immunocompromised status and history of COVID-19.
  5. eImmunocompromised status was removed from the list of core variables owing to lack of model convergence.
  6. fObesity was removed from the list of core variables owing to lack of model convergence.
  7. gObesity and history of COVID-19 were removed from the list of core variables owing to lack of model convergence.
Back to article page